Free Trial
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Intra-Cellular Therapies logo
$131.87 0.00 (0.00%)
As of 04/2/2025

About Intra-Cellular Therapies Stock (NASDAQ:ITCI)

Key Stats

Today's Range
$131.87
$131.87
50-Day Range
$128.20
$131.92
52-Week Range
$64.09
$131.98
Volume
N/A
Average Volume
1.47 million shs
Market Capitalization
$14.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$109.70
Consensus Rating
Hold

Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intra-Cellular Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

ITCI MarketRank™: 

Intra-Cellular Therapies scored higher than 18% of companies evaluated by MarketBeat, and ranked 293rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 10 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Intra-Cellular Therapies has only been the subject of 3 research reports in the past 90 days.

  • Read more about Intra-Cellular Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Intra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Intra-Cellular Therapies' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ITCI.
  • Dividend Yield

    Intra-Cellular Therapies does not currently pay a dividend.

  • Dividend Growth

    Intra-Cellular Therapies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ITCI.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Intra-Cellular Therapies this week, compared to 7 articles on an average week.
  • Search Interest

    11 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.60% of the stock of Intra-Cellular Therapies is held by insiders.

  • Percentage Held by Institutions

    92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intra-Cellular Therapies' insider trading history.
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

Trump Makes Major Crypto Announcement
Trump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick.
Intra-Cellular Therapies
See More Headlines

ITCI Stock Analysis - Frequently Asked Questions

Intra-Cellular Therapies' stock was trading at $83.52 on January 1st, 2025. Since then, ITCI stock has increased by 57.9% and is now trading at $131.87.
View the best growth stocks for 2025 here
.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its quarterly earnings data on Friday, February, 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.08. The biopharmaceutical company earned $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 9.93% and a negative net margin of 14.07%.

Top institutional shareholders of Intra-Cellular Therapies include CIBRA Capital Ltd (0.39%), Bank of New York Mellon Corp (0.33%), Syquant Capital Sas (0.25%) and Rhumbline Advisers (0.12%). Insiders that own company stock include Sharon Mates, Rory B Riggs, Joel S Marcus, Mark Neumann, Suresh K Durgam, Nostrand Robert L Van, Lawrence J Hineline and Michael Halstead.
View institutional ownership trends
.

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/21/2025
Today
5/01/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITCI
Employees
560
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$109.70
High Stock Price Target
$132.00
Low Stock Price Target
$74.00
Potential Upside/Downside
-16.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-139,670,000.00
Pretax Margin
-13.87%

Debt

Sales & Book Value

Annual Sales
$680.50 million
Price / Cash Flow
N/A
Book Value
$6.15 per share
Price / Book
21.44

Miscellaneous

Free Float
103,563,000
Market Cap
$14.05 billion
Optionable
Optionable
Beta
0.69

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ITCI) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners